Results from studies included in GlaxoSmithKline PLC's proposal for a mouth spray nicotine replacement therapy prompt the US Food and Drug Administration to question the product's "real world" efficacy.
In its briefing materials published 16 September for its Nonprescription Drugs Advisory Committee to consider GSK's new drug application...





